ArticleHuman vaccines & immunotherapeutics2026
Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States.
Chunyan Yan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.